All lobbying filings

CGCN GROUP, LLC

Lobbying for FRESENIUS KABI USA, LLC · Healthcare company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$30,000.00

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Taxation/Internal Revenue Code

U.S. manufacturing incentives.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.